Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

10.98USD
4:00pm EDT
Change (% chg)

$0.16 (+1.48%)
Prev Close
$10.82
Open
$10.87
Day's High
$11.04
Day's Low
$10.66
Volume
65,492
Avg. Vol
182,424
52-wk High
$13.97
52-wk Low
$7.68

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $1,145.61
Shares Outstanding(Mil.): 105.88
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -1.32 -- --
ROI: -58.05 1.52 12.66
ROE: -276.33 0.25 14.84

BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40

* LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

May 03 2018

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

Mar 26 2018

Competitors

Earnings vs. Estimates